Emcutix Biopharmaceuticals Limited, a subsidiary of Emcure Pharmaceuticals Limited, has entered an exclusive in-licensing agreement with WiQo, a renowned Italian derma-cosmetic and medical device company. This strategic collaboration grants Emcutix the rights to import, distribute, and promote WiQo’s innovative product, PRX-PLUS, in India.
PRX-PLUS is a groundbreaking, non-invasive skin treatment that delivers immediate skin tightening without injections or recovery time. It offers a pain-free alternative to traditional aesthetic treatments and is suitable for all skin types and seasons. This innovative formula has gained popularity globally, with over 40,000 dermatologists using WiQo’s patented solutions and more than 8 million needle-free procedures performed worldwide since 2011.
The dermatology market in India is witnessing impressive growth, driven by rising disposable incomes and increased skincare awareness. With the Indian dermatology market valued at around 1.8 billion USD and an expected growth rate of 11-12%, Emcutix’s partnership with WiQo is poised to redefine the future of skincare in the region.
This alliance is a step forward in Emcutix’s commitment to offering effective dermatological solutions in India, catering to both prescription and consumer skincare needs. The introduction of PRX-PLUS aligns with Emcutix’s goal to provide innovative, science-backed products that enhance the lives of consumers across the country.
